Who are N-3 Polyunsaturated Fatty Acids's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Polyunsaturated fatty acids omega-3.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/n-3-polyunsaturated-fatty-acids.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

N-3 Polyunsaturated Fatty Acids — Competitive Intelligence Brief

N-3 Polyunsaturated Fatty Acids (N-3 Polyunsaturated Fatty Acids) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Omega-3 fatty acid / Lipid-modifying agent. Area: Cardiovascular.

phase 3 Omega-3 fatty acid / Lipid-modifying agent GPR120, GPR40, PPAR-γ, LXR Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

N-3 Polyunsaturated Fatty Acids (N-3 Polyunsaturated Fatty Acids) — Sixth Affiliated Hospital, Sun Yat-sen University. N-3 polyunsaturated fatty acids reduce triglycerides and modulate inflammatory pathways through incorporation into cell membranes and effects on eicosanoid metabolism.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
N-3 Polyunsaturated Fatty Acids TARGET	N-3 Polyunsaturated Fatty Acids	Sixth Affiliated Hospital, Sun Yat-sen University	phase 3	Omega-3 fatty acid / Lipid-modifying agent	GPR120, GPR40, PPAR-γ, LXR
Polyunsaturated fatty acids omega-3	Polyunsaturated fatty acids omega-3	Hospital San Juan de la Cruz	phase 3	Lipid-modifying agent; nutraceutical	Multiple: GPR120, GPR40, PPAR-γ, LXR; membrane incorporation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Omega-3 fatty acid / Lipid-modifying agent class)

Sixth Affiliated Hospital, Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). N-3 Polyunsaturated Fatty Acids — Competitive Intelligence Brief. https://druglandscape.com/ci/n-3-polyunsaturated-fatty-acids. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab